TG Therapeutics targets $525M BRIUMVI revenue in 2025 while advancing subcutaneous formulation and pivotal trials

Earnings Call Insights: TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2024

Management View

• CEO Michael Weiss highlighted the strong full-year 2024 U.S. revenue of $310 million for BRIUMVI, exceeding initial guidance and reflecting the therapy’s value in treating relapsing multiple sclerosis (